Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Primers Provide Significant Breakthrough in Assay Sensitivity

Published: Thursday, September 20, 2012
Last Updated: Thursday, September 20, 2012
Bookmark and Share
Swift Biosciences, Inc. has announced a new addition to its line of myT® Primer reagents for the detection of key cancer mutations.

myT BRAF-Ultra, an ultrasensitive version of myT BRAF, provides 0.01% sensitivity down to single copy detection of BRAF mutations and is now available from Swift.  myT BRAF-Ultra can detect less than 10 copies of mutant BRAF V600E/K with very low breakthrough amplification from a background of 10,000 Swift-myT-BRAF-Press-Releas.gifwild-type genomic DNA copies. While myT BRAF-Ultra works well with fresh frozen and FFPE samples, this level of sensitivity also makes the product ideal for use when the sample material is limiting or where the target is present at very low concentration, such as with circulating tumor cells (CTCs), serum, plasma and needle biopsies. Each myT BRAF-Ultra package includes sufficient reagents to assess up to 14 samples when run in triplicate, plus a positive and a negative control.

myT BRAF-Ultra is the newest addition to the myT Primer line of products.  The first product in the family, myT BRAF, can detect 1% mutant BRAF V600E/K present in a background of 1,000 wild-type genomic DNA copies with no breakthrough amplification from wild-type, resulting in assays that give definitive Yes/No answers over a wide dynamic range and reduce or completely eliminate the need for delta Ct methods to call results.  Each myT BRAF package includes sufficient reagents to assess up to 28 samples plus a positive and a negative control.

The extreme selectivity and reproducibility of myT Primers provides an increased level of confidence and convenience in qPCR assays and makes them ideal for use when the sample material is limiting or where the target is present at very low concentration.  Additional myT Primer reagents will be coming soon, including primers for high sensitivity detection of KRAS mutations in codons 12 and 13.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Discovering the First Farmers
Genetic analyses reveal a collection of highly distinct groups in the Near East and Europe at the dawn of agriculture.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Ice Bucket Challenge Instrumental in Gene Discovery
Donations from the ALS Ice Bucket Chellenge allowed for the largest-ever study of inherited ALS, which identified a new ALS gene.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!